

# CHIVA method for the treatment of varicose veins

## Protocol information

**Review number:** 1671

### Authors

Sergi Bellmunt-Montoya<sup>1</sup>, Jose Maria Escribano<sup>2</sup>, Jaume Dilme<sup>1</sup>, Maria José Martínez-Zapata<sup>3</sup>

<sup>1</sup>Angiology, Vascular and Endovascular Surgery, Hospital de la Santa Creu i Sant Pau, IBB Sant Pau, Barcelona, Spain

<sup>2</sup>Angiology, Vascular and Endovascular Surgery, Hospital Universitario Vall d'Hebron, Barcelona, Spain

<sup>3</sup>Iberoamerican Cochrane Centre. Universitat Autònoma de Barcelona. Institute of Biomedical Research Sant Pau (IIB Sant Pau), Barcelona, CIBER Epidemiología y Salud Pública (CIBERESP), Spain, Barcelona, Spain

Citation example: Bellmunt-Montoya S, Escribano JM, Dilme J, Martínez-Zapata MJ. CHIVA method for the treatment of varicose veins. *Cochrane Database of Systematic Reviews*, Issue . Art. No.: . DOI: .

### Contact person

#### *Sergi Bellmunt-Montoya*

Vascular Surgeon

Angiology, Vascular and Endovascular Surgery

Hospital de la Santa Creu i Sant Pau, IBB Sant Pau

Sant Quinti No. 89

Barcelona

08041

Spain

E-mail: [sbellmunt@santpau.cat](mailto:sbellmunt@santpau.cat)

### Dates

**Assessed as Up-to-date:** Not provided

**Date of Search:** Not provided

**Next Stage Expected:** 19 January 2013

**Protocol First Published:** Not specified

**Review First Published:** Not specified

**Last Citation Issue:** Not specified

### What's new

Date	Event	Description
------	-------	-------------

### History

Date	Event	Description
------	-------	-------------

## Abstract

[Background](#)

[Objectives](#)

[Search methods](#)

[Selection criteria](#)

[Data collection and analysis](#)

[Main results](#)

[Authors' conclusions](#)

## Plain language summary

[Summary title]

[Summary text]

## Background

### Description of the condition

Venous insufficiency is the inability to drive venous blood flow to the heart in response to tissue drainage, thermoregulation, and hemodynamic reserve. Venous insufficiency may entail all the factors involved in venous return, the venous wall and

valve system, posture, the muscle pump, and respiratory and venule-capillary bed factors. When referring to the syndrome of chronic venous insufficiency (CVI), all signs and symptoms characteristic of this disease of the lower limbs must be addressed. Subjectively, patients report pain, fatigue, heaviness, warmth, swelling, etc., which are more intense when standing and under environmental conditions of heat and humidity ([Vanhouette 1997](#)). Objectively, varicose veins, reticular veins, edema, skin changes, and healed or active ulcers, or both, are found.

CVI is a chronic disease of multicausal origin with a slow evolution of symptoms. CVI complications (ulcers, phlebitis, superficial or deep vein thrombosis, skin complications) often appear years or even decades after the onset of symptoms ([Kurz 1999](#)). The prevalence of CVI in the general population depends on the outcome considered. It has been estimated that the prevalence of trunk varices ranges from 30% to 40% in the general population ([Lee 2003](#)) and that 15% of females and 9% of males have reflux confined to the superficial venous system ([Allan 2000](#)). According to [Carpentier 2004](#), varicose veins of any type can be detected in up to 50% of women in the general population.

The introduction of duplex scanning in the study of CVI has allowed in vivo knowledge of venous hemodynamics ([Franceschi 1997](#)). In addition to allowing the completion of a morphological study, this exploration facilitates the mapping of the hemodynamics of the venous system, providing precise information on any changes or abnormalities ([Cavezzi 2007](#); [Coleridge-Smith 2006](#); [Labropoulos 2005](#); [Lambropoulos 2001](#); [Nicolaidis 2000](#)).

Treatment of CVI depends on the state of development of the disease ([Agus 2001](#)). There are several therapeutic options that can be used in combination to treat this disease. These therapies cannot cure the disease but can improve symptoms and prevent complications. Treatments for CVI include hygiene and postural measures such as elevation of the legs or walking around to keep the muscle pump working, compression therapy ([Nelson 2000](#); [Nelson 2011](#); [O'Meara 2009](#)), topical treatment ([Aziz 2011](#); [Cullum 2010](#); [Jull 2008](#); [Kranke 2004](#); [O'Meara 2010](#); [Palfreyman 2006](#)), drug therapy ([Martinez-Zapata 2005](#); [O'Meara 2010](#)), sclerotherapy ([Tisi 2006](#)), laser therapy ([Flemming 1999](#)), radiofrequency ablation ([Nesbitt 2011](#)) and surgery ([Rigby 2004](#)).

During the 20th century, the first major step in the treatment of varicose veins of the lower limbs was removing the saphenous vein through a metal loop, designed by Keller in 1905. In May 1906, Keller also described the technique of endoluminal stripping. Two years later Babcock first used a flebo-extractor similar to that used today ([Lofgren 1977](#)). In 1966, Muller's ambulatory phlebectomy was described ([Muller 1966](#)). However, based on the available literature, treatment that involves these techniques cannot prevent varicosity recurrence ([Blomgren 2004](#); [Perrin 2000](#); [Winterborn 2004](#)). Besides the possibility of surgical errors, this treatment does not allow for the prevention of the development of new varicose veins ([Labropoulos 2005](#)) or the remodeling of the venous network of subcutaneous tissue ([Juan 2002](#)). Surgery that removes saphenous veins is generally associated with the presence of varicosities or telangiectasias, and sometimes leads to a clinical cosmetic outcome that is poorer than before surgery. These inconveniences are difficult to justify in patients with clinical grade C2 of the Clinical picture, Etiology, Anatomic distribution and Pathophysiology (CEAP) classification ([Porter 1995](#)) ([Table 1](#)).

### Description of the intervention

In 1988, Franceschi ([Franceschi 1988](#)) described a procedure for the treatment of CVI based on hemodynamic performance of the elements that determine the emergence of varicose veins with preservation of the superficial venous system. Franceschi called this procedure the Conservative Hemodynamics of Ambulatory Venous Insufficiency (CHIVA) cure.

Although normally applied via surgery, CHIVA is not a technique but a strategy that can be delivered via surgery, sclerosis, laser or endovascular procedures. The CHIVA method is based on the modification of the hemodynamics of the venous system to eliminate varicose dilatations. This theory is supported by the findings of Mendoza and Escribano ([Escribano 2003](#); [Mendoza 2011](#)). The authors demonstrate that CHIVA produces a regression of the diameter size of the saphenous vein (1.6 to 2.6 mm) and the femoral vein (0.4 to 0.7 mm) involved in the venous shunt ([Escribano 2003](#); [Mendoza 2011](#)).

### How the intervention might work

Primary varicose veins are hemodynamically characterized by the existence of a retrograde circuit or venous-venous shunt ([Goren 1996](#)). This circuit consists of a retrograde proximal reflux point (escape point) from which blood from the deep venous system is discharged into the superficial venous system, usually the saphenous veins. The hydrostatic pressure column, between the escape point and the point of re-entry into the deep venous system, generally comprises the saphenous vein and the perforating vein re-entry. This point of venous retrograde re-entry circuit drains back into the deep venous system.

The CHIVA method is a minimally invasive surgery procedure, usually performed under local anesthesia, based on the findings of a careful analysis of the hemodynamic superficial venous network by echo-doppler.

The principles underlying the CHIVA method are:

1. fragmentation of the venous pressure column;
2. disconnecting the venous-venous shunts;
3. preservation of the perforators re-entry;
4. abolition of undrained superficial varicose veins.

The aim of the CHIVA treatment is to decrease the hydrostatic column pressure to disrupt venous-venous shunts without removing the saphenous vein and the venous drainage of the superficial tissues of the limb.

### Why it is important to do this review

There are some clinical trials that provide evidence about the efficacy of the CHIVA strategy compared with stripping (the

gold standard treatment) ([Carandina 2008](#); [Iborra 2006](#); [Pares 2010](#)). CHIVA is one of the few strategies that treat varicose veins without seeking their destruction.

## Objectives

To evaluate the efficacy and safety of the CHIVA technique compared with other procedures to treat varicose veins.

## Methods

### Criteria for considering studies for this review

#### *Types of studies*

Randomized controlled trials (RCTs).

#### *Types of participants*

Males and females over 18 years of age suffering from CVI, CEAP stage from 2 to 6.

#### *Types of interventions*

RCTs that assess the technique of CHIVA compared with other procedures to treat varicose veins, such as drugs, compressive measures, laser therapy, radiofrequency, stripping, sclerotherapy or any other.

#### *Types of outcome measures*

##### Primary outcomes

Recurrence of varicosity, defined as the appearance of new varicose veins after a minimum length of follow-up of one year.

##### Secondary outcomes

Re-treatment, defined as patients' need for a new intervention due to persistent varicose veins or new varicose veins in the same leg and the same area.

Clinic or aesthetic changes after a minimum length of follow-up of one month after the intervention as assessed by the following.

- Objective signs:
  - free from reflux, checked by echo-doppler;
  - edema measured by the dichotomous variable 'edema' and the continuous variables 'ankle perimeter circumference' and 'volume of the leg';
  - skin manifestations such as venous ulcers and trophic alterations, which may include telangiectasia (small red points on the skin caused by permanently opened tiny blood vessels), reticular veins (dilated veins which show as a net-like pattern on the skin), varicose veins (permanently dilated veins), or lipodermatosclerosis (a hardening of the skin which may gain a red or brown pigmentation and is accompanied by wasting of the subcutaneous fat).
- Subjective symptoms:
  - pain;
  - cramps;
  - restless legs;
  - itching;
  - feeling of heaviness in the legs;
  - swelling;
  - paresthesias (abnormal sensations, such as prickling, burning, tingling).
- Global assessment measures:
  - disease-specific quality of life (QoL) scales (e.g. CVIIQ or Veines-qol) or satisfaction of participants, or both.

#### Side effects

- participants who experience adverse events during the trial, as reported by questionnaire or related by the participants and specified within the publication, such as hematoma, infection, superficial or deep venous thrombosis, lung embolism, nerve injury.

### Search methods for identification of studies

#### *Electronic searches*

The Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator (TSC) will search the Specialised Register and the Cochrane Central Register of Controlled Trials (CENTRAL), part of *The Cochrane Library*, [www.thecochranelibrary.com](http://www.thecochranelibrary.com). See [Appendix 1](#) for details of the search strategy which will be used to search CENTRAL. The Specialised Register is maintained by the TSC and is constructed from weekly electronic searches of MEDLINE, EMBASE, CINAHL, AMED, and through handsearching relevant journals. The full list of the databases, journals and conference proceedings which have been searched, as well as the search strategies used are described in the [Specialised Register](#) section of the Cochrane Peripheral Vascular Diseases Group module in *The Cochrane Library* ([www.thecochranelibrary.com](http://www.thecochranelibrary.com)).

The following trial databases will be searched by the TSC for details of ongoing and unpublished studies:

- World Health Organization International Clinical Trials Registry <http://apps.who.int/trialsearch/>;
- ClinicalTrials.gov <http://clinicaltrials.gov/>;
- Current Controlled Trials <http://www.controlled-trials.com/>.

### ***Searching other resources***

We will scrutinize reference lists of identified RCTs, systematic reviews and meta-analyses in order to find further trials.

## **Data collection and analysis**

### ***Selection of studies***

Two authors (SB and MJM) will independently assess the eligibility of the studies identified in the search. If there are any disagreements, a third author will independently evaluate the study and will discuss it with the rest of the team. We will classify eligible studies as included or excluded. If study classification is unclear, we will contact the authors to obtain any pertinent clarification.

### ***Data extraction and management***

Two authors (SB and MJM) will collect data independently on a previously tested standardized form. Data will include methodological quality, characteristics of study participants, characteristics of the intervention and control groups, and outcome characteristics of each group of participants. One review author (MJM) will enter the data into Review Manager 5.1 and will perform the appropriate analyses.

### ***Assessment of risk of bias in included studies***

Two authors (SB and MJM) will assess the quality of the studies, specifically examining the randomization method (sequence generation and allocation concealment); whether the intervention was masked (blinded) to the participants, investigators and outcome assessors; incomplete outcome data; percentage of patients lost to follow-up; estimate of sample size; and whether the study included an intention-to-treat (ITT) analysis.

Once this information has been gathered, the authors will classify each study into one of the three levels of risk of bias: low, unclear or high risk of bias, based on the criteria specified in the Cochrane Handbook for Systematic Reviews of Interventions ([Higgins 2011](#)).

### ***Measures of treatment effect***

For each study we will consider relative risks (RRs) for dichotomous variables and mean differences (MDs) for continuous variables. If the continuous variables in the studies are measured in different scales, we will calculate the standardized mean difference (SMD). We will also calculate the number needed to treat for an additional beneficial outcome (NNTB) and the number needed to treat for an additional harmful outcome (NNTH).

### ***Unit of analysis issues***

The unit of analysis will be the individual participants randomized in the included clinical trials. We will collect and analyze a single measurement for each outcome from each participant.

### ***Dealing with missing data***

We will contact study authors if more information is needed, as well as to clarify any doubts that may arise regarding missing data.

The main analysis will be an 'available case analysis', analyzing data as provided in the individual studies.

Secondarily, we will also complete an intention-to-treat sensitivity analysis of dichotomous variables, imputing data using a worst case scenario. We will enter missing values for participants who withdrew or were lost to follow-up as negative events.

### ***Assessment of heterogeneity***

We will examine the characteristics of each study to detect clinical heterogeneity. We will deem an  $I^2$  statistic greater than 50% as substantial heterogeneity. We will also study the sources of heterogeneity.

### ***Assessment of reporting biases***

If a reasonable number of studies (more than 10) are included in the review, we will assess publication bias by means of a funnel plot.

### ***Data synthesis***

We will determine the global effect estimate for each variable through a meta-analysis of the individual effect measures of each outcome. We will apply the statistical method of Mantel-Haenszel for dichotomous measures and the inverse variance for continuous measures using a fixed-effect model. If  $I^2$  is greater than 50%, we will use a random-effects model. If heterogeneity is greater than 75%, we will not pool the results. We will perform all statistical analyses using Review Manager 5.1.

### ***Subgroup analysis and investigation of heterogeneity***

The authors anticipate the following as sources of clinical heterogeneity and plan to conduct subgroup analyses comparing:

- 1) type of procedure that was used to implement the CHIVA method, i.e. open surgery, endovascular surgery, sclerosis or

laser technique;

2) type of comparison assessed, i.e. CHIVA versus drugs, CHIVA versus leg compression, CHIVA versus any surgery (laser therapy, stripping, radiofrequency, etc.).

### ***Sensitivity analysis***

We will use sensitivity analysis to assess the strength of the results and to explain possible heterogeneity between the studies. We will re-analyze data by:

1. comparing unpublished studies (if there are any) versus published studies;
2. comparing studies with high risk of bias versus low risk of bias;
3. analyzing data by intention to treat.

## **Results**

### **Description of studies**

#### ***Results of the search***

#### ***Included studies***

#### ***Excluded studies***

#### **Risk of bias in included studies**

#### ***Allocation (selection bias)***

#### ***Blinding (performance bias and detection bias)***

#### ***Incomplete outcome data (attrition bias)***

#### ***Selective reporting (reporting bias)***

#### ***Other potential sources of bias***

#### **Effects of interventions**

## **Discussion**

### **Summary of main results**

### **Overall completeness and applicability of evidence**

### **Quality of the evidence**

### **Potential biases in the review process**

### **Agreements and disagreements with other studies or reviews**

## **Authors' conclusions**

### **Implications for practice**

### **Implications for research**

## **Acknowledgements**

### **Contributions of authors**

Conceiving the review: SB, JME

Designing the review: SB, MJM

Co-ordinating the review: MJM

Designing electronic search strategy: Cochrane PVD Group editorial base

Screening search results: SB, MJM

Obtaining copies of trials: SB, MJM

Appraising quality of papers: SB, MJM

Abstracting data from papers: SB, MJM

Data management for the review: MJM

Entering data into RevMan: MJM

Analysis of data: MJM

Interpretation of data: all authors

Writing the review: MJM, SB, JME

Draft the final review: all authors

Guarantor for the review: SB, MJM

## **Declarations of interest**

None known

## Differences between protocol and review

### Published notes

### Characteristics of studies

#### Characteristics of included studies

*Footnotes*

#### Characteristics of excluded studies

*Footnotes*

#### Characteristics of studies awaiting classification

*Footnotes*

#### Characteristics of ongoing studies

*Footnotes*

## Summary of findings tables

### Additional tables

#### 1 CEAP Clinical Classification (C)

Class	Clinical Indication
0	No visible or palpable signs of venous disease
1	Telangiectases or reticular veins
2	Varicose veins
3	Edema
4	Skin changes ascribed to venous disease (e.g., pigmentation, venous eczema, lipodermatosclerosis)
5	Skin changes as defined here with healed ulceration
6	Skin changes as defined here with active ulceration

*Footnotes*

## References to studies

### Included studies

### Excluded studies

### Studies awaiting classification

### Ongoing studies

## Other references

### Additional references

#### **Agus 2001**

Agus GB, Allegra C, Arpaia G, Botta G, Cataldi A, Gasbarro V, et al. Guidelines for the diagnosis and treatment of chronic venous insufficiency. *International Angiology* 2001;20(1):1-37.

#### **Allan 2000**

Allan PL, Bradbury AW, Evans CJ, Lee AJ, Vaughan Ruckley C, Fowkes FG. Patterns of reflux and severity of varicose veins in the general population - Edinburgh Vein Study. *European Journal of Vascular and Endovascular Surgery* 2000;20(5):470-7.

#### **Aziz 2011**

Aziz Z, Cullum N, Flemming K. Electromagnetic therapy for treating venous leg ulcers. *Cochrane Database of Systematic Reviews* 2011, Issue 3. Art. No.: CD002933 DOI: 10.1002/14651858.CD002933.pub4.

#### **Blomgren 2004**

Blomgren L, Johansson G, Dahlberg-AKerman A, Norén A, Brundin C, Nordström E, et al. Recurrent varicose veins: Incidence, risk factors and groin anatomy. *European Journal of Vascular and Endovascular Surgery* 2004;27(3):269-74.

#### **Carandina 2008**

Carandina S, Mari C, De Palma M, Marcellino MG, Cisno C, Legnaro A, et al. Varicose Vein Stripping vs Haemodynamic

Correction (CHIVA): a long term randomised trial. *European Journal of Vascular and Endovascular Surgery* 2008;35(2):230-7.

### ***Carpentier 2004***

Carpentier PH, Maricq HR, Biro C, Ponçot-Makinen CO, Franco A. Prevalence, risk factors, and clinical patterns of chronic venous disorders of lower limbs: A population-based study in France. *Journal of Vascular Surgery* 2004;40(4):650-9.

### ***Cavezzi 2007***

Cavezzi A, Labropoulos N, Partsch H, Ricci S, Caggiati A, Myers K, et al. Duplex ultrasound investigation of the veins in chronic venous disease of the lower limbs. UIP consensus document. Part II. Anatomy. *Vasa* 2007;36(1):62-71.

### ***Coleridge-Smith 2006***

Coleridge-Smith P, Labropoulos N, Partsch H, Myers K, Nicolaidis A, Cavezzi A. Duplex ultrasound investigation of the veins in chronic venous disease of the lower limbs. UIP consensus document. Part I. Basic principles. *European Journal of Vascular and Endovascular Surgery* 2006 ;31(1):83-92.

### ***Cullum 2010***

Cullum NA, Al-Kurdi D, Bell-Syer SEM. Therapeutic ultrasound for venous leg ulcers. *Cochrane Database of Systematic Reviews* 2010, Issue 6. Art. No.: CD001180 DOI: 10.1002/14651858.CD001180.pub3.

### ***Escribano 2003***

Escribano JM, Juan J, Bofill R, Maeso J, Rodríguez-Mori A, Matas M. Durability of reflux-elimination by a minimal invasive CHIVA procedure on patients with varicose veins. A 3-year prospective case study. *European Journal of Vascular and Endovascular Surgery* 2003;25(2):159-63.

### ***Flemming 1999***

Flemming K, Cullum NA. Laser therapy for venous leg ulcers. *Cochrane Database of Systematic Reviews* 1999, Issue 1. Art. No.: CD001182 DOI: 10.1002/14651858.CD001182.

### ***Franceschi 1988***

Franceschi C. Théorie et pratique de la cure conservatrice de l'insuffisance veineuse en ambulatoire. Precy-sous-Thil. France: Editions de l'Armançon, 1988.

### ***Franceschi 1997***

Franceschi C. Measures and interpretation of venous flow in stress tests. Manual compression and Parana manoeuver. Dynamic reflux index and Psatakis index [Mesures et interprétation des flux veineux lors des manoeuvres de stimulation. Compressions manuelles et manoeuvre de Paranà. Indice dynamique de reflux (IDR) et indice de Psatakis]. *Journal des Maladies Vasculaires* 1997;22(2):91-5.

### ***Goren 1996***

Goren G, Yellin AE. Hemodynamic principles of varicose vein therapy. *Dermatologic Surgery* 1996;22(7):657-62.

### ***Higgins 2011***

Higgins JPT, Green S, editors. *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from [www.cochrane-handbook.org](http://www.cochrane-handbook.org).

### ***Iborra 2006***

Iborra-Ortega E, Barjau-Urrea E, Vila-Coll R, Ballon-Carazas H, Cairols-Castellote MA. Comparative study of two surgical techniques in the treatment of varicose veins of the lower extremities: results after five years of follow-up [Estudio comparativo de dos técnicas quirúrgicas en el tratamiento de las varices de las extremidades inferiores: resultados tras cinco años de seguimiento]. *Angiología* 2006;58(6):459-68.

### ***Juan 2002***

Juan J, Escribano JM, Maeso J. Hemodynamic after stripping of varicose vein [Hämodynamik des Varizenrezidivs nach Strippingoperation]. In: 18 Jahreskongress 2002 der Deutschen Gessellschaft für GefäBchirurgie – Gesellschaft für vaskuläre und endovaskuläre Chirurgie. Würzburg (Germany). 2002.

### ***Jull 2008***

Jull AB, Rodgers A, Walker N. Honey as a topical treatment for wounds. *Cochrane Database of Systematic Reviews* 2008, Issue 4. Art. No.: CD005083 DOI: 10.1002/14651858.CD005083.pub2.

### ***Kranke 2004***

Kranke P, Bennett MH, Debus SE, Roeckl-Wiedmann I, Schnabel A. Hyperbaric oxygen therapy for chronic wounds. *Cochrane Database of Systematic Reviews* 2004, Issue 1. Art. No.: CD004123 DOI: 10.1002/14651858.CD004123.pub2.

### ***Kurz 1999***

Kurz X, Kahn SR, Abenhain L, Clement D, Norgren L, Baccaglini U, et al. Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis and management. Summary of an evidence-based report of the VEINES task force. *Venous*

Insufficiency Epidemiologic and Economic Studies. *International Angiology* 1999;18(2):83-102.

### ***Labropoulos 2005***

Labropoulos N, León L, Kwon S, Tassiopoulos A, González-Fajardo JA, Kang SS, Manssur MA. Study of the venous reflux progression. *Journal of Vascular Surgery* 2005;41(2):291-5.

### ***Lambropoulos 2001***

Labropoulos N, Tiongson J, Pryor L, Tassiopoulos AK, Kang SS, Mansour MA, et al. Nonsaphenous superficial vein reflux. *Journal of Vascular Surgery* 2001;34(5):872-7.

### ***Lee 2003***

Lee AJ, Evans CJ, Allan PL, Ruckley CV, Fowkes FG. Lifestyle factors and the risk of varicose veins: Edinburgh Vein Study. *Journal of Clinical Epidemiology* 2003;56(2):171-9.

### ***Lofgren 1977***

Lofgren EP. The operative treatment of varicose veins. In: Rutherford RB, editors(s). *Vascular surgery*. Philadelphia: WB Saunders, 1977:1169-75.

### ***Martinez-Zapata 2005***

Martinez-Zapata MJ, Bonfill Cosp X, Moreno RM, Vargas E, Capellà D. Phlebotonics for venous insufficiency. *Cochrane Database of Systematic Reviews* 2005, Issue 3. Art. No.: CD003229 DOI: 10.1002/14651858.CD003229.pub2.

### ***Mendoza 2011***

Mendoza E, Berger V, Zollmann C, Bomhoff M, Amsler F. Diameter-reduction of the great saphenous vein and common femoral vein after CHIVA. *Phlebologie* 2011;40:73-8.

### ***Muller 1966***

Muller R. Treatment of varicose veins by ambulatory phlebectomy [Traitement des varices par phlébectomie ambulatoire]. *Phlebologie* 1966;19(4):277-9.

### ***Nelson 2000***

Nelson EA, Bell-Syer SEM, Cullum NA, Webster J. Compression for preventing recurrence of venous ulcers. *Cochrane Database of Systematic Reviews* 2000, Issue 4. Art. No.: CD002303 DOI: 10.1002/14651858.CD002303.

### ***Nelson 2011***

Nelson EA, Mani R, Thomas K, Vowden K. Intermittent pneumatic compression for treating venous leg ulcers. *Cochrane Database of Systematic Reviews* 2011, Issue 2. Art. No.: CD001899 DOI: 10.1002/14651858.CD001899.pub3.

### ***Nesbitt 2011***

Nesbitt C, Eiffel RK, Coyne P, Badri H, Bhattacharya V, Stansby G. Endovenous ablation (radiofrequency and laser) and foam sclerotherapy versus conventional surgery for great saphenous vein varices. *Cochrane Database of Systematic Reviews* 2011, Issue 10. Art. No.: CD005624 DOI: 10.1002/14651858.CD005624.pub2.

### ***Nicolaidis 2000***

Nicolaidis AN. Investigation of chronic venous insufficiency. A consensus statement. *Circulation* 2000;102:e126-63.

### ***O'Meara 2009***

O'Meara S, Cullum NA, Nelson EA. Compression for venous leg ulcers. *Cochrane Database of Systematic Reviews* 2009, Issue 1. Art. No.: CD000265 DOI: 10.1002/14651858.CD000265.pub2.

### ***O'Meara 2010***

O'Meara S, Al-Kurdi D, Ologun Y, Ovington LG. Antibiotics and antiseptics for venous leg ulcers. *Cochrane Database of Systematic Reviews* 2010, Issue 1. Art. No.: CD003557 DOI: 10.1002/14651858.CD003557.pub3.

### ***Palfreyman 2006***

Palfreyman SSJ, Nelson EA, Lochiel R, Michaels JA. Dressings for healing venous leg ulcers. *Cochrane Database of Systematic Reviews* 2006, Issue 3. Art. No.: CD001103 DOI: 10.1002/14651858.CD001103.pub2.

### ***Pares 2010***

Parés JO, Juan J, Tellez R, Mata A, Moreno C, Quer FX, et al. Varicose vein surgery: stripping versus the CHIVA Method: a randomized controlled trial. *Annals of Surgery* 2010;251(4):624-31.

### ***Perrin 2000***

Perrin MR, Guex JJ, Ruckley CV, de Palma RG, Royle JP, Eklof B, et al. Recurrent varices after surgery (REVAS), a consensus document. *REVAS Group. Cardiovascular Surgery* 2000;8(4):233-45.

### ***Porter 1995***

Porter JM, Moneta GL. Reporting standards in venous disease: an update. *International Consensus Committee on Chronic*



Venous Disease. *Journal of Vascular Surgery* 1995;21(4):635–45.

### **Rigby 2004**

Rigby KA, Palfreyman SSJ, Beverley C, Michaels JA. Surgery versus sclerotherapy for the treatment of varicose veins. *Cochrane Database of Systematic Reviews* 2004, Issue 4. Art. No.: CD004980 DOI: 10.1002/14651858.CD004980.

### **Tisi 2006**

Tisi PV, Beverley C, Rees A. Injection sclerotherapy for varicose veins. *Cochrane Database of Systematic Reviews* 2006, Issue 4. Art. No.: CD001732 DOI: 10.1002/14651858.CD001732.pub2.

### **Vanhouette 1997**

Vanhouette PM, Corcaud S, de Montrion C. Venous disease: from pathophysiology to quality of life. *Angiology* 1997;48(7):559-67.

### **Winterborn 2004**

Winterborn R, Foy C, Earnshaw JJ. Causes of varicose vein recurrence: late results of a randomized controlled trial of stripping the long saphenous vein. *Journal of Vascular Surgery* 2004;40(4):634-9.

## **Other published versions of this review**

### **Classification pending references**

## **Data and analyses**

## **Figures**

## **Sources of support**

### **Internal sources**

- Iberoamerican Cochrane Center, Spain

### **External sources**

- Chief Scientist Office, Scottish Government Health Directorates, Scottish Government, UK  
The PVD Group editorial base is supported by the Chief Scientist Office.
- Associazione "Umanizzazione" della Chirurgia, Italy  
This organization is a not-for-profit organization that promotes formative and scientific sessions (scientific meetings, workshops etc.) principally in relation to venous hemodynamics of the lower limbs. This organization partially finances this review because it has an interest in the independent assessment of the CHIVA method but it does not have influence on the review process.

## **Feedback**

## **Appendices**

### **1 CENTRAL search strategy**

```
#1 MeSH descriptor Varicose Veins explode all trees
#2 (varicos* near3 (vein* or veno*))
#3 (tortu* near3 (vein* or veno*))
#4 (incomp* near3 (vein* or veno*))
#5 (insuffic* near3 (vein* or veno*))
#6 (saphenous near3 reflux)
#7 MeSH descriptor Saphenous Vein, this term only with qualifier: SU
#8 (GSV)
#9 MeSH descriptor Venous Insufficiency explode all trees
#10 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9)
#11 (CHIVA):ti,ab,kw
#12 ambulatory near5 Hemodynamic
#13 Conservat* near5 Hemodynam*
#14 ambulatory near5 surg*
#15 ambulatory near5 strip*
#16 haemodynamic near5 surgery
#17 hemodynamic near5 surgery
#18 MeSH descriptor Ambulatory Surgical Procedures, this term only
#19 MeSH descriptor Surgical Procedures, Minimally Invasive, this term only
#20 (#11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19)
#21 (#10 AND #20)
```

## **Graphs**

